Repurposing Anticancer Drugs To Tackle Malaria |
| |
Authors: | Dr Yohann Le Govic Prof Sandrine Houzé Prof Nicolas Papon |
| |
Affiliation: | 1. Laboratoire de Parasitologie-Mycologie, Centre de Biologie Humaine, CHU Amiens Picardie – site Sud, Amiens, France;2. CNR du Paludisme, AP-HP, Hôpital Bichat – Claude-Bernard, Laboratoire de Parasitologie-Mycologie, UMR261 Merit, Université de Paris, Paris, France;3. Host-Pathogen Interaction Study Group (GEIHP), EA 3142, UNIV Angers, UNIV Brest, SFR 4208 ICAT, Angers, France |
| |
Abstract: | Despite considerable efforts, malaria remains one of the most devastating infectious disease worldwide. In the absence of an effective vaccine, the prophylaxis and management of Plasmodium infections still rely on the therapeutic use of antimalarial agents. However, the emergence of resistant parasites has jeopardized the efficiency of virtually all antimalarial drugs, including artemisinin combination therapies (ACTs). Thus, there is an urgent need for innovative treatments with novel targets to avoid or overcome drug resistance. In this context, Huang & colleagues prioritized compounds that can block the activity of epigenetic enzymes, and described the discovery of a selective P. falciparum histone deacetylase (HDAC) inhibitor with high activity against various stages of the parasite. These findings may pave the way toward developing new lead compounds with broad-spectrum activity, thus facilitating malaria treatment and elimination. |
| |
Keywords: | Plasmodium falciparum malaria quisinostat histone deacetylases resistance |
|
|